Targeted Alpha Therapy – Optimising Survival in Advanced Prostate Cancer
Targeted alpha therapy (TAT) is the delivery of high-energy alpha particles to cancer cells and the tumour microenvironment to treat cancer. After a survival benefit was shown for radium-223 versus standard of care in patients with metastatic castration-resistant prostate cancer (mCRPC), radium-223 became the first approved TAT.1–3 In the European Society for Medical Oncology (ESMO) […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!